ReviewSeminars in oncology2012
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.
Review in Seminars in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214688 (A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation), which is not on this map. Cited by 187 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies
Who cites it
187 citing papers in PubMed, 1 synthesis or guideline pooled it, 328 citations in OpenAlex.
- In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Bone marrow transplantation · 2017Pooled it
- Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial.Blood advances · 2025Trial
- Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.Blood advances · 2022Trial
- Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.Blood advances · 2020Trial
- The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.Bone marrow transplantation · 2016Trial
- Trial
- OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation.European journal of haematology · 2016Trial
- Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.Bone marrow transplantation · 2015Trial
- Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.Bone marrow transplantation · 2015Trial
- Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Blood · 2015Trial
- Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Early inflammatory complications after haploidentical hematopoietic stem cell transplantation with post transplant cyclophosphamide for acute leukemia: a pediatric multicenter experience.Bone marrow transplantation · 2026Article
- Fludarabine, cyclophosphamide and 2 Gy TBI with PT-Cy as a single platform for haplo and unrelated donor allo-SCT in older AML or MDS patients.Bone marrow transplantation · 2026Article
- Outcomes of an optimized ciclosporin-free haploidentical HSCT protocol in paediatric patients with cerebral adrenoleukodystrophy.British journal of haematology · 2026Article
- Daphnetin prevents acute graft-versus-host disease by suppressing donor T cell expansion and function.Inflammopharmacology · 2026Article
- Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.Bone marrow transplantation · 2026Article
- Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.Blood advances · 2026Article
- Article
- Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant Cyclophosphamide.Advances in experimental medicine and biology · 2026Review
127 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative therapy for many hematologic and immunologic diseases. Further, partial or full donor hematopoietic chimerism following alloSCT may be sufficient to guarantee immunologic tolerance to solid organs from the same donor, obviating any requirement for prolonged pharmacologic immunosuppression. Despite alloSCT's potential, the procedure is beset by two major limitations. The first relates to the procedure's toxicity, including conditioning regimen toxicity, graft-versus-host disease (GVHD), and infection. The second limitation is the lack of histocompatible donors. A human leukocyte antigen (HLA)-matched sibling or unrelated donor cannot be identified expeditiously for up to 40% of patients. Historically, alloSCT from partially HLA-mismatched, or HLA-haploidentical, relatives has been complicated by unacceptably high incidences of graft rejection, severe GVHD, and non-relapse mortality. Recently, our groups have developed a method to selectively deplete alloreactive cells in vivo by administering high doses of cyclophosphamide in a narrow window after transplantation. Using high-dose, post-transplantation cyclophosphamide (PT/Cy), crossing the HLA barrier in alloSCT is now feasible and donors can be found for nearly all patients. This review discusses the history of HLA-haploidentical SCT, recent clinical results, and immunologic mechanisms of action of high-dose PT/Cy for prevention of graft rejection and GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.